Boehringer Ingelheim presented new patient-reported outcomes data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, showing that HERNEXEOS® (zongertinib tablets) as an initial treatment in HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC) improved physical function and reduced symptom burden, according to a company press release dated May 22, 2026.
The data, from a Phase I trial, indicated that patients receiving HERNEXEOS monotherapy reported better scores on the EORTC QLQ-C30 questionnaire for physical function and key symptoms like fatigue, pain, and dyspnea compared to baseline. The findings suggest a favorable benefit-risk profile for this targeted therapy in a biomarker-defined population.
HERNEXEOS is an oral, irreversible tyrosine kinase inhibitor designed to selectively target HER2 mutations while sparing wild-type EGFR, potentially reducing off-target toxicities. The drug received accelerated approval from the U.S. Food and Drug Administration in 2024 for adult patients with previously treated HER2-mutant advanced NSCLC.
Boehringer Ingelheim continues to evaluate HERNEXEOS in ongoing clinical trials, including as a first-line treatment and in combination with other agents, to expand its role in HER2-driven cancers.
